(0.16%) 5 477.90 points
(0.04%) 39 128 points
(0.49%) 17 805 points
(0.06%) $80.88
(-5.04%) $2.62
(-0.90%) $2 309.80
(-0.36%) $28.77
(2.90%) $1 015.00
(0.34%) $0.936
(0.52%) $10.66
(0.51%) $0.792
(0.86%) $88.24
-18.25% $ 0.0327
Live Chart Being Loaded With Signals
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia...
Stats | |
---|---|
Volumen de hoy | 19.05M |
Volumen promedio | 9.38M |
Capitalización de mercado | 4.34M |
EPS | $0.130 ( Q1 | 2024-05-23 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0399 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-31 | Moch Kenneth I | Buy | 200 000 | Ordinary Shares |
2024-01-31 | Wills Stephen T | Buy | 200 000 | Ordinary Shares |
2024-01-31 | Tomasello Shawn | Buy | 200 000 | Ordinary Shares |
2024-01-31 | Adams Julian | Buy | 200 000 | Ordinary Shares |
2024-01-31 | Simantov Ronit | Buy | 480 319 | Ordinary Shares |
INSIDER POWER |
---|
95.68 |
Last 90 transactions |
Buy: 8 073 627 | Sell: 418 674 |
Volumen Correlación
Gamida Cell Ltd Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Gamida Cell Ltd Correlación - Moneda/Commodity
Gamida Cell Ltd Finanzas
Annual | 2023 |
Ingresos: | $1.78M |
Beneficio Bruto: | $-1.69M (-94.96 %) |
EPS: | $-0.570 |
FY | 2023 |
Ingresos: | $1.78M |
Beneficio Bruto: | $-1.69M (-94.96 %) |
EPS: | $-0.570 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-440 000 (0.00 %) |
EPS: | $-2.42 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Gamida Cell Ltd
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico